Evidence Level:Sensitive: C3 – Early Trials
New
Title:
374 A first-in-human Phase 1/2 open label trial evaluating the safety, pharmacology, and preliminary efficacy of VT1021 in subjects with advanced solid tumors
Excerpt:...VT1021 has demonstrated activities in reprogramming the TME which resulted in a high disease control rate in subjects with tumors expressing both high CD36 and high CD47.
DOI:10.1136/jitc-2020-SITC2020.0374